Literature DB >> 30113239

Factors that drive the increasing use of FFPE tissue in basic and translational cancer research.

E F Gaffney1, P H Riegman2, W E Grizzle3, P H Watson4.   

Abstract

The decision to use 10% neutral buffered formalin fixed, paraffin embedded (FFPE) archival pathology material may be dictated by the cancer research question or analytical technique, or may be governed by national ethical, legal and social implications (ELSI), biobank, and sample availability and access policy. Biobanked samples of common tumors are likely to be available, but not all samples will be annotated with treatment and outcomes data and this may limit their application. Tumors that are rare or very small exist mostly in FFPE pathology archives. Pathology departments worldwide contain millions of FFPE archival samples, but there are challenges to availability. Pathology departments lack resources for retrieving materials for research or for having pathologists select precise areas in paraffin blocks, a critical quality control step. When samples must be sourced from several pathology departments, different fixation and tissue processing approaches create variability in quality. Researchers must decide what sample quality and quality tolerance fit their specific purpose and whether sample enrichment is required. Recent publications report variable success with techniques modified to examine all common species of molecular targets in FFPE samples. Rigorous quality management may be particularly important in sample preparation for next generation sequencing and for optimizing the quality of extracted proteins for proteomics studies. Unpredictable failures, including unpublished ones, likely are related to pre-analytical factors, unstable molecular targets, biological and clinical sampling factors associated with specific tissue types or suboptimal quality management of pathology archives. Reproducible results depend on adherence to pre-analytical phase standards for molecular in vitro diagnostic analyses for DNA, RNA and in particular, extracted proteins. With continuing adaptations of techniques for application to FFPE, the potential to acquire much larger numbers of FFPE samples and the greater convenience of using FFPE in assays for precision medicine, the choice of material in the future will become increasingly biased toward FFPE samples from pathology archives. Recognition that FFPE samples may harbor greater variation in quality than frozen samples for several reasons, including variations in fixation and tissue processing, requires that FFPE results be validated provided a cohort of frozen tissue samples is available.

Entities:  

Keywords:  DNA; FFPE; RNA; biobank; cancer; consent; frozen tissue; molecular target; paraffin processing; pathologists; pathology archive; pre-analysis; protein extraction; reproducibility; standards

Mesh:

Substances:

Year:  2018        PMID: 30113239     DOI: 10.1080/10520295.2018.1446101

Source DB:  PubMed          Journal:  Biotech Histochem        ISSN: 1052-0295            Impact factor:   1.718


  25 in total

1.  The Utilization of Biospecimens: Impact of the Choice of Biobanking Model.

Authors:  William E Grizzle; Marianna J Bledsoe; Sameer Al Diffalha; Dennis Otali; Katherine C Sexton
Journal:  Biopreserv Biobank       Date:  2019-06       Impact factor: 2.300

2.  Quantitative Proteomic Analysis Using Formalin-Fixed, Paraffin-Embedded (FFPE) Human Cardiac Tissue.

Authors:  Omid Azimzadeh; Michael J Atkinson; Soile Tapio
Journal:  Methods Mol Biol       Date:  2021

3.  The Use of Human Tissues for Research: What Investigators Need to Know.

Authors:  Marianna J Bledsoe; William E Grizzle
Journal:  Altern Lab Anim       Date:  2022-07-08       Impact factor: 2.438

4.  Practical tips to using formalin-fixed paraffin-embedded tissue archives for molecular diagnostics in a South African setting.

Authors:  Barbara S van Deventer; Lorraine du Toit-Prinsloo; Chantal van Niekerk
Journal:  Afr J Lab Med       Date:  2022-06-23

5.  Comparison of manual and automated digital image analysis systems for quantification of cellular protein expression.

Authors:  T Jagomast; C Idel; L Klapper; P Kuppler; L Proppe; S Beume; M Falougy; D Steller; S G Hakim; A Offermann; M C Roesch; K L Bruchhage; S Perner; J Ribbat-Idel
Journal:  Histol Histopathol       Date:  2022-02-11       Impact factor: 2.130

6.  Overcoming the Challenges of High Quality RNA Extraction from Core Needle Biopsy.

Authors:  Hanne Locy; Rohann J M Correa; Dorien Autaers; Ann Schiettecatte; Jan Jonckheere; Wim Waelput; Louise Cras; Stefanie Brock; Stefaan Verhulst; Keith Kwan; Marian Vanhoeij; Kris Thielemans; Karine Breckpot
Journal:  Biomolecules       Date:  2021-04-22

7.  Do Tissues Fixed in a Non-crosslinking Fixative Require a Dedicated Formalin-free Processor?

Authors:  Sonia G Frasquilho; Ignacio Sanchez; Changyoung Yoo; Laurent Antunes; Camille Bellora; William Mathieson
Journal:  J Histochem Cytochem       Date:  2021-05-19       Impact factor: 4.137

8.  Protoblock - A biological standard for formalin fixed samples.

Authors:  Yensi Flores Bueso; Sidney P Walker; Glenn Hogan; Marcus J Claesson; Mark Tangney
Journal:  Microbiome       Date:  2020-08-22       Impact factor: 14.650

9.  Histologic and molecular features in pathologic human menisci from knees with and without osteoarthritis.

Authors:  Farrah A Monibi; Tania Pannellini; Miguel Otero; Russell F Warren; Scott A Rodeo
Journal:  J Orthop Res       Date:  2021-04-19       Impact factor: 3.494

10.  High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification.

Authors:  Yi Zhu; Tobias Weiss; Qiushi Zhang; Rui Sun; Bo Wang; Xiao Yi; Zhicheng Wu; Huanhuan Gao; Xue Cai; Guan Ruan; Tiansheng Zhu; Chao Xu; Sai Lou; Xiaoyan Yu; Ludovic Gillet; Peter Blattmann; Karim Saba; Christian D Fankhauser; Michael B Schmid; Dorothea Rutishauser; Jelena Ljubicic; Ailsa Christiansen; Christine Fritz; Niels J Rupp; Cedric Poyet; Elisabeth Rushing; Michael Weller; Patrick Roth; Eugenia Haralambieva; Silvia Hofer; Chen Chen; Wolfram Jochum; Xiaofei Gao; Xiaodong Teng; Lirong Chen; Qing Zhong; Peter J Wild; Ruedi Aebersold; Tiannan Guo
Journal:  Mol Oncol       Date:  2019-09-18       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.